Eris Lifesciences has completed acquisition of 19% equity stake in Swiss Parenterals (Swiss) from the promoters of the company. Earlier, the company had acquired 51% equity stake in Swiss Parenterals.
The acquisition of Swiss Parenterals will help company to strengthen India footprint through the launch of a domestic Injectables-focused Branded Formulations business.
Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.
